Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Two months after launching Pep2Tango Therapeutics, VC firm Versant Ventures is unveiling another obesity-focused biotech in ...

Takeda is taking back the home license for a phase 3-ready depression drug as part of an amendment to its multi-asset ...

After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ...

BioAge Labs has given up on its lead obesity candidate. Weeks after stopping a trial in response to phase 2 data, the biotech has jettisoned the molecule and shifted its focus to a preclinical ...

Just days after President Trump imposed broad restrictions on communications, meetings, travel and public appearances at the ...

Cell therapy biotech Aurion is moving forward with plans to IPO despite a pending lawsuit from one of its existing investors.

Leap Therapeutics has come crashing down to earth. The biotech axed plans to advance into phase 3 in gastric cancer on the basis of midstage data, sending its stock down 60% to below $1, but it is ...

Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

The FDA has tapped Sara Brenner to serve as acting commissioner as it awaits new leadership from the Trump administration to ...

The author of the seminal cancer biography The Emperor Of All Maladies and the co-founder of LinkedIn are looking to connect ...